ID

17565

Descrizione

Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth; ODM derived from: https://clinicaltrials.gov/show/NCT00106964

collegamento

https://clinicaltrials.gov/show/NCT00106964

Keywords

versioni (1)
  1. 24/09/16 24/09/16 -
Caricato su

24 settembre 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility HIV Infection NCT00106964

Inglese

Eligibility HIV Infection NCT00106964

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
documented hiv+
Descrizione

HIV Seropositivity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019699
age 12 to < 25 years
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
history of no or one hepatitis b vaccination
Descrizione

Hepatitis B vaccination

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0474232
not pregnant.
Descrizione

Pregnancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
females engaging in sexual intercourse must be willing to practice an approved method of birth control throughout the completion of the vaccine phase of the study.
Descrizione

Gender Sex Behavior Contraceptive methods

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0036864
UMLS CUI [1,3]
C0700589
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of > 1 hepatitis b vaccination
Descrizione

Hepatitis B vaccination Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0474232
UMLS CUI [1,2]
C1265611
serologic evidence of past or present hepatitis b infection: anti-hepatitis b surface antigen (hbsag), hbs-ag or anti- hepatitis b core antigen (hbcag)
Descrizione

Hepatitis B Evidence Serologic | Hepatitis B Virus Surface Antibody | Hepatitis B Surface Antigens | Antibody to hepatitis B core antigen

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0019163
UMLS CUI [1,2]
C3887511
UMLS CUI [1,3]
C0205473
UMLS CUI [2]
C0369334
UMLS CUI [3]
C0019168
UMLS CUI [4]
C0312631
previous allergic reaction to hepatitis a or b vaccinations or to yeast, thimerosal or aluminum.
Descrizione

Allergic Reaction Hepatitis A immunization | Allergic Reaction Hepatitis B vaccination | Allergic Reaction Yeasts | Allergic Reaction Thimerosal | Allergic Reaction Aluminum

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C0419735
UMLS CUI [2,1]
C1527304
UMLS CUI [2,2]
C0474232
UMLS CUI [3,1]
C1527304
UMLS CUI [3,2]
C0043393
UMLS CUI [4,1]
C1527304
UMLS CUI [4,2]
C0039867
UMLS CUI [5,1]
C1527304
UMLS CUI [5,2]
C0002367
active opportunistic infection or current treatment for known or suspected active serious bacterial infection at the pre-entry exam.
Descrizione

Opportunistic Infections | Therapeutic procedure Bacterial Infections Serious

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0029118
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0004623
UMLS CUI [2,3]
C0205404
presence of any known grade >= 3 clinical or laboratory toxicity at the time of pre-entry per toxicity tables.
Descrizione

Toxicity Grade

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2826262
anticipation of long-term corticosteroid therapy or within 3 months preceding study randomization. use of non-steroidal, anti-inflammatory agents and inhaled or topical corticosteroids are allowed.
Descrizione

Steroid therapy Long-term anticipation | Anti-Inflammatory Agents, Non-Steroidal | inhaled steroids | Topical corticosteroids

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0149783
UMLS CUI [1,2]
C0443252
UMLS CUI [1,3]
C0679106
UMLS CUI [2]
C0003211
UMLS CUI [3]
C2065041
UMLS CUI [4]
C0304604
receipt of any restricted medicine listed in the protocol section 8.1.3 within 3 months preceding randomization.
Descrizione

Pharmaceutical Preparations Restricted

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0443288
receipt of immune globulin product or plasma product within 6 months preceding randomization
Descrizione

Immunoglobulins | Human plasma, blood product

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021027
UMLS CUI [2]
C0304926
receipt of licensed blood product or transfusion or any licensed vaccine within 4 weeks preceding randomization.
Descrizione

Blood product Licensed | Transfusion | Vaccine Licensed

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0023636
UMLS CUI [2]
C0005841
UMLS CUI [3,1]
C0042210
UMLS CUI [3,2]
C0023636
known or suspected diseases of the immune system, other than hiv, or treatment for a malignancy within 3 months of randomization.
Descrizione

Immune System Diseases | HIV | Therapeutic procedure Malignant Neoplasms

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021053
UMLS CUI [2]
C0019682
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0006826
other serious, acute or chronic medical or surgical conditions must be approved by the protocol chair.
Descrizione

Other medical condition | Surgical aspects

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3843040
UMLS CUI [2]
C0038895
Ritorna all'inizio della pagina

Similar models

Eligibility HIV Infection NCT00106964

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
HIV Seropositivity
Item
documented hiv+
boolean
C0019699 (UMLS CUI [1])
Age
Item
age 12 to < 25 years
boolean
C0001779 (UMLS CUI [1])
Hepatitis B vaccination
Item
history of no or one hepatitis b vaccination
boolean
C0474232 (UMLS CUI [1])
Pregnancy
Item
not pregnant.
boolean
C0032961 (UMLS CUI [1])
Gender Sex Behavior Contraceptive methods
Item
females engaging in sexual intercourse must be willing to practice an approved method of birth control throughout the completion of the vaccine phase of the study.
boolean
C0079399 (UMLS CUI [1,1])
C0036864 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Hepatitis B vaccination Quantity
Item
history of > 1 hepatitis b vaccination
boolean
C0474232 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Hepatitis B Evidence Serologic | Hepatitis B Virus Surface Antibody | Hepatitis B Surface Antigens | Antibody to hepatitis B core antigen
Item
serologic evidence of past or present hepatitis b infection: anti-hepatitis b surface antigen (hbsag), hbs-ag or anti- hepatitis b core antigen (hbcag)
boolean
C0019163 (UMLS CUI [1,1])
C3887511 (UMLS CUI [1,2])
C0205473 (UMLS CUI [1,3])
C0369334 (UMLS CUI [2])
C0019168 (UMLS CUI [3])
C0312631 (UMLS CUI [4])
Allergic Reaction Hepatitis A immunization | Allergic Reaction Hepatitis B vaccination | Allergic Reaction Yeasts | Allergic Reaction Thimerosal | Allergic Reaction Aluminum
Item
previous allergic reaction to hepatitis a or b vaccinations or to yeast, thimerosal or aluminum.
boolean
C1527304 (UMLS CUI [1,1])
C0419735 (UMLS CUI [1,2])
C1527304 (UMLS CUI [2,1])
C0474232 (UMLS CUI [2,2])
C1527304 (UMLS CUI [3,1])
C0043393 (UMLS CUI [3,2])
C1527304 (UMLS CUI [4,1])
C0039867 (UMLS CUI [4,2])
C1527304 (UMLS CUI [5,1])
C0002367 (UMLS CUI [5,2])
Opportunistic Infections | Therapeutic procedure Bacterial Infections Serious
Item
active opportunistic infection or current treatment for known or suspected active serious bacterial infection at the pre-entry exam.
boolean
C0029118 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C0004623 (UMLS CUI [2,2])
C0205404 (UMLS CUI [2,3])
Toxicity Grade
Item
presence of any known grade >= 3 clinical or laboratory toxicity at the time of pre-entry per toxicity tables.
boolean
C2826262 (UMLS CUI [1])
Steroid therapy Long-term anticipation | Anti-Inflammatory Agents, Non-Steroidal | inhaled steroids | Topical corticosteroids
Item
anticipation of long-term corticosteroid therapy or within 3 months preceding study randomization. use of non-steroidal, anti-inflammatory agents and inhaled or topical corticosteroids are allowed.
boolean
C0149783 (UMLS CUI [1,1])
C0443252 (UMLS CUI [1,2])
C0679106 (UMLS CUI [1,3])
C0003211 (UMLS CUI [2])
C2065041 (UMLS CUI [3])
C0304604 (UMLS CUI [4])
Pharmaceutical Preparations Restricted
Item
receipt of any restricted medicine listed in the protocol section 8.1.3 within 3 months preceding randomization.
boolean
C0013227 (UMLS CUI [1,1])
C0443288 (UMLS CUI [1,2])
Immunoglobulins | Human plasma, blood product
Item
receipt of immune globulin product or plasma product within 6 months preceding randomization
boolean
C0021027 (UMLS CUI [1])
C0304926 (UMLS CUI [2])
Blood product Licensed | Transfusion | Vaccine Licensed
Item
receipt of licensed blood product or transfusion or any licensed vaccine within 4 weeks preceding randomization.
boolean
C0456388 (UMLS CUI [1,1])
C0023636 (UMLS CUI [1,2])
C0005841 (UMLS CUI [2])
C0042210 (UMLS CUI [3,1])
C0023636 (UMLS CUI [3,2])
Immune System Diseases | HIV | Therapeutic procedure Malignant Neoplasms
Item
known or suspected diseases of the immune system, other than hiv, or treatment for a malignancy within 3 months of randomization.
boolean
C0021053 (UMLS CUI [1])
C0019682 (UMLS CUI [2])
C0087111 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])
Other medical condition | Surgical aspects
Item
other serious, acute or chronic medical or surgical conditions must be approved by the protocol chair.
boolean
C3843040 (UMLS CUI [1])
C0038895 (UMLS CUI [2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial